Immunotherapy Brings 'Radical Change' to Lung Cancer Treatment

Marina Chiara Garassino, M.D., medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, talks about how immunotherapy agents have vastly improved the treatment field of patients with non-small cell lung cancer.

Over the past few years, there have been exciting advancements with the addition of anti-PD1 and anti-PD-L1 agents to the lung cancer space. Now, even more trials are investigating the use of immunotherapy in both the neoadjuvant and adjuvant settings.